atrasentan has been researched along with Carcinoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castelo, B; Espinosa, E; Merino, M; Pinto, A; Redondo, A; Zamora, P | 1 |
| Carr, RA; Groenewegen, G; Humerickhouse, RA; Isaacson, JD; Janus, TJ; Leahy, TW; Voest, E; Zonnenberg, BA | 1 |
| Carducci, M; Jimeno, A | 1 |
2 review(s) available for atrasentan and Carcinoma
| Article | Year |
|---|---|
Targeting the endothelin axis in prostate carcinoma.
Topics: Atrasentan; Bone and Bones; Carcinoma; Cell Proliferation; Clinical Trials as Topic; Endothelins; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrrolidines | 2012 |
Atrasentan: targeting the endothelin axis in prostate cancer.
Topics: Atrasentan; Carcinoma; Clinical Trials, Phase III as Topic; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A | 2004 |
1 trial(s) available for atrasentan and Carcinoma
| Article | Year |
|---|---|
Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Atrasentan; Carcinoma; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrrolidines; Time Factors | 2003 |